IL-12/p40 binding proteins
    21.
    发明专利

    公开(公告)号:AU2006265932A1

    公开(公告)日:2007-01-11

    申请号:AU2006265932

    申请日:2006-06-29

    Applicant: ABBOTT LAB

    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

    INTERLEUKIN-13 BINDING PROTEINS
    22.
    发明专利

    公开(公告)号:ZA200901526B

    公开(公告)日:2018-11-28

    申请号:ZA200901526

    申请日:2009-03-03

    Applicant: ABBOTT LAB

    Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

    METHODS FOR TRANSFORMING YEAST
    24.
    发明专利

    公开(公告)号:NZ587766A

    公开(公告)日:2013-06-28

    申请号:NZ58776609

    申请日:2009-03-03

    Applicant: ABBOTT LAB

    Abstract: NZ 587766 Disclosed is a method of preparing a yeast library by electroporation of yeast cells, the method comprising the steps of: incubating the yeast cells in a solution comprising lithium acetate (LiAc) and dithiothreitol (DTT); providing a suspension comprising vector DNA, insert DNA, yeast cells, 0.1 to 10 M sorbitol, and 0.1 to 10 mM CaCl2 or MgCl2; and electroporating the suspension at 0.5kV/cm to greater than 12.5kV/cm with a capacitance of about 10 to about 50 mu ?F.

    PROTEÍNAS DE LA UNIÓN A IL-12/P40 (DIVISIONAL EXP. 9599)

    公开(公告)号:CR20130150A

    公开(公告)日:2013-05-23

    申请号:CR20130150

    申请日:2013-04-03

    Applicant: ABBOTT LAB

    Abstract: Proteínas de unión a IL-12 p40, en particular anticuerpos que se unen a la interleuquina-12 humana (hIL-12) y/o IL-23 humana (hIL-23). Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por hIL-12 y/o hIL-23 y neutralizan la actividad de hIL-12 y/o hIL-23 in vitro y in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antígeno del mismo. También se provee un método de elaboración y un método de uso de los anticuerpos de la invención.

    METHODS FOR TRANSFORMING YEAST
    27.
    发明专利

    公开(公告)号:SG188846A1

    公开(公告)日:2013-04-30

    申请号:SG2013016084

    申请日:2009-03-03

    Applicant: ABBOTT LAB

    Abstract: Methods for Transforming Yeast AbstractThis invention is directed to the transformtion of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.Figure I

    PROTEINAS DE UNION A INTERLEUQUINA-13

    公开(公告)号:DOP2009000033A

    公开(公告)日:2009-03-15

    申请号:DO2009000033

    申请日:2009-03-04

    Applicant: ABBOTT LAB

    Abstract: Proteínas de unión a !L-13. Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por la hIL-13 y neutralizan la actividad de la hIL-13 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antigeno del mismo. Tambien se provee un método de elaboración y un método de uso de los anticuerpos de la invención. Los anticuerpos, o porciones de anticuerpo, de la invención son de utilidad para detectar la hIL-13 y para inhibir la actividad hIL-13, por ejemplo, en un sujeto humano que sufre de un trastorno en el cual la actividad de la hIL-13 sea perjudicial.

    29.
    发明专利
    未知

    公开(公告)号:BRPI0611714A2

    公开(公告)日:2009-01-13

    申请号:BRPI0611714

    申请日:2006-06-29

    Applicant: ABBOTT LAB

    Abstract: The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Patent Agency Ranking